ATE66817T1 - Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. - Google Patents
Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.Info
- Publication number
- ATE66817T1 ATE66817T1 AT86307397T AT86307397T ATE66817T1 AT E66817 T1 ATE66817 T1 AT E66817T1 AT 86307397 T AT86307397 T AT 86307397T AT 86307397 T AT86307397 T AT 86307397T AT E66817 T1 ATE66817 T1 AT E66817T1
- Authority
- AT
- Austria
- Prior art keywords
- parenteral injection
- biologically active
- active proteins
- stable formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/780,551 US4816440A (en) | 1985-09-26 | 1985-09-26 | Stable formulation of biologically active proteins for parenteral injection |
EP86307397A EP0217645B1 (de) | 1985-09-26 | 1986-09-25 | Stabile Formulierung biologisch aktiver Proteine zur parenteralen Injektion |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE66817T1 true ATE66817T1 (de) | 1991-09-15 |
Family
ID=25119894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT86307397T ATE66817T1 (de) | 1985-09-26 | 1986-09-25 | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. |
Country Status (7)
Country | Link |
---|---|
US (1) | US4816440A (de) |
EP (1) | EP0217645B1 (de) |
JP (1) | JPS6272625A (de) |
AT (1) | ATE66817T1 (de) |
AU (1) | AU590618B2 (de) |
CA (1) | CA1295245C (de) |
DE (1) | DE3681243D1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0645551B2 (ja) * | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | インタ−ロイキン−2組成物 |
DE3621828A1 (de) * | 1986-06-28 | 1988-01-14 | Biotest Pharma Gmbh | Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff |
US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
US4973478A (en) * | 1987-07-20 | 1990-11-27 | Allelix Biopharmaceuticals, Inc. | Treating inflammation with hepatocyte stimulating factor interferon β2 |
NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
US4965191A (en) * | 1988-02-12 | 1990-10-23 | Eastman Kodak Company | Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand |
US5198212A (en) * | 1988-10-31 | 1993-03-30 | University Of Lousville Research Foundation Incorporated | Method and compositions for treatment of trauma-associated sepsis with gamma interferon |
US5530100A (en) * | 1990-05-07 | 1996-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Methods for purification of recombinantly produced proteins |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
JPH0588553U (ja) * | 1991-10-04 | 1993-12-03 | チェン ロン−シウン | 浮玉自動オフ式点滴輸液管 |
FR2684878B1 (fr) * | 1991-12-12 | 1994-02-11 | Roussel Uclaf | Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation. |
US5545723A (en) * | 1994-03-15 | 1996-08-13 | Biogen Inc. | Muteins of IFN-β |
US5714371A (en) * | 1995-05-12 | 1998-02-03 | Schering Corporation | Method for refolding insoluble aggregates of hepatitis C virus protease |
US6923956B1 (en) | 1997-09-23 | 2005-08-02 | Rentschler Biotechnologie Gmbh | Liquid interferon-β formulations |
US7582311B1 (en) | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
US7651703B2 (en) * | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
EP1935431A3 (de) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2 |
US7544354B2 (en) * | 2000-10-27 | 2009-06-09 | Novartis Vaccines And Diagnostics | Methods of protein purification and recovery |
PT1343518E (pt) * | 2000-11-07 | 2009-08-03 | Novartis Vaccines & Diagnostic | Composições de interferão estabilizadas |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
OA12506A (en) * | 2001-04-18 | 2006-05-29 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors. |
AU2003285075B2 (en) * | 2002-10-29 | 2009-10-29 | Durect Corporation | Stabilized, solid-state polypeptide particles |
AU2003303635B2 (en) * | 2002-12-26 | 2009-07-23 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
TWI364295B (en) * | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
ATE545434T1 (de) * | 2003-10-23 | 2012-03-15 | Novartis Vaccines & Diagnostic | Stabilisierte zusammensetzungen |
PT1682178E (pt) | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
EP1885858A2 (de) * | 2005-05-19 | 2008-02-13 | Bayer Schering Pharma Aktiengesellschaft | Behandlung von krankheiten unter anwendung eines verbesserten regulierten expressionssystems |
US20060292609A1 (en) * | 2005-05-19 | 2006-12-28 | Schering Aktiengesellschaft | Interferon-beta gene therapy using an improved, regulated expression system |
US20080076729A1 (en) * | 2005-05-19 | 2008-03-27 | Schering Aktiengesellachaft | Interferon-beta gene therapy using an improved, regulated expression system |
US20070179113A1 (en) * | 2005-05-19 | 2007-08-02 | Schering Aktiengesellachaft | GM-CSF gene therapy for Crohn's disease using an improved regulated expression system |
WO2009045553A1 (en) * | 2007-10-05 | 2009-04-09 | Barofold, Inc. | High pressure treatment of aggregated interferons |
DE102012101864A1 (de) * | 2012-03-06 | 2013-09-12 | Gramme-Revit Gmbh | Mittel zur Behandlung von Allergien und anderen Erkrankungen |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3658970A (en) * | 1969-07-23 | 1972-04-25 | John Mcclure Carroll | Injectable lauric acid |
US3667929A (en) * | 1969-07-30 | 1972-06-06 | George W Fleming Jr | Method of effecting dissolution of solutes in water and compositions therefor |
CA1113926A (en) * | 1975-08-27 | 1981-12-08 | Johannes Van Der Vies | Pharmaceutical preparation adapted for oral administration |
US4331653A (en) * | 1977-08-18 | 1982-05-25 | Robert Brown | Composition for a topical cream for curtailing bleeding and treating skin disorders |
JPS56104812A (en) * | 1980-01-23 | 1981-08-20 | Sankyo Co Ltd | Production of cephalosporin compound preparation for rectal infusion |
JPS5780314A (en) * | 1980-11-09 | 1982-05-19 | Kyoto Yakuhin Kogyo Kk | Pharmaceutical preparation to be medicated to rectum |
JPS5788126A (en) * | 1980-11-19 | 1982-06-01 | Kyoto Yakuhin Kogyo Kk | Agent for promoting peroral and transvaginal absorption and preparation containing the same |
JPS58116498A (ja) * | 1981-12-28 | 1983-07-11 | Takeda Chem Ind Ltd | Il‐2をコードする新規伝令rnaの製造法 |
US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
EP0091539B2 (de) * | 1982-03-31 | 1996-11-27 | Ajinomoto Co., Inc. | Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
US4463940A (en) * | 1982-10-18 | 1984-08-07 | Mock Russell V | Apparatus and method for continuous stacking of signatures using opposed floating conveyors |
EP0127426A1 (de) * | 1983-05-23 | 1984-12-05 | Takeda Chemical Industries, Ltd. | Perkutane pharmazeutische Zusammensetzungen zur äusserlichen Anwendung |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
-
1985
- 1985-09-26 US US06/780,551 patent/US4816440A/en not_active Expired - Lifetime
-
1986
- 1986-09-02 CA CA000517300A patent/CA1295245C/en not_active Expired - Fee Related
- 1986-09-25 DE DE8686307397T patent/DE3681243D1/de not_active Expired - Fee Related
- 1986-09-25 EP EP86307397A patent/EP0217645B1/de not_active Expired - Lifetime
- 1986-09-25 AT AT86307397T patent/ATE66817T1/de not_active IP Right Cessation
- 1986-09-26 JP JP61226310A patent/JPS6272625A/ja active Pending
- 1986-09-26 AU AU63182/86A patent/AU590618B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0217645A3 (en) | 1987-09-23 |
JPS6272625A (ja) | 1987-04-03 |
DE3681243D1 (de) | 1991-10-10 |
AU590618B2 (en) | 1989-11-09 |
AU6318286A (en) | 1987-04-02 |
EP0217645A2 (de) | 1987-04-08 |
US4816440A (en) | 1989-03-28 |
CA1295245C (en) | 1992-02-04 |
EP0217645B1 (de) | 1991-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3681243D1 (de) | Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. | |
DE3689870D1 (de) | Formulierung für rekombinantes beta-Interferon, Verfahren zur Gewinnung und Stabilisierung des beta-Interferons und dessen Verwendung. | |
ATE66614T1 (de) | Insulinzubereitung fuer nicht-parenterale verabreichung. | |
ATE74512T1 (de) | Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren. | |
FI874706A0 (fi) | Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi | |
DE69531314D1 (de) | Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen | |
PH22556A (en) | Heterocyclic compounds, pharmaceutical compositions containing the same and method of use thereof | |
MY128629A (en) | Stabilized interleukin 2 | |
FI870219A0 (fi) | Hypoglykemiska tiazolidindioner. | |
ES8603271A1 (es) | Un metodo de producir una composicion de interleuquina-2 | |
ES2009216A6 (es) | Metodo de preparar un derivado de interleucina-lalfa. | |
ATE96807T1 (de) | Rcrf und aehnliche verbindungen. | |
ATE44652T1 (de) | Zubereitung mit gehalt an stabilisiertes polypeptid mit gamma-interferon aktivitaet. | |
IT1187828B (it) | Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi | |
SE8503097D0 (sv) | Glutaminsyra- och asparginsyraderivat | |
FI882605A (fi) | Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta | |
NO955126D0 (no) | Mat-og/eller farmasöytisk blanding med lavt polyamininnhold og terapeutiske anvendelser derav | |
ATE79267T1 (de) | Stabilisierung eines fuer therapeutische zwecke bestimmten interleukin-2-praeparates. | |
DK0641216T3 (da) | Farmaceutisk præparat indeholdende IL-6 | |
DK425487A (da) | Pharmaceutisk aktive derivater af glutamin- og asparginsyre | |
NO863026L (no) | Fenyletanolaminderivater-preparater med kontinuerlig avgivelse. | |
EP0219839A3 (de) | Derivat des Interleukin-2, seine Herstellung und Verwendung | |
JPS6479125A (en) | Antitumor agent | |
ZA891784B (en) | Peptides with pharmaceutical activity | |
SU1387399A1 (ru) | Питательная среда для культивирования лептоспир |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |